Research compound supplied in Australia by Pulse Biolabs for laboratory use. Available in 15mg.
After a meal, the gut sends hormone signals that shape insulin release and fullness. Tirzepatide activates the receptors for two of them, and in Australia the same molecule is a registered prescription medicine.
Tirzepatide (LY3298176) is a synthetic 39-amino-acid peptide that activates two incretin receptors, GLP-1 and GIP, the receivers for gut hormones involved in insulin release and the feeling of fullness after eating. Researchers study it to understand what engaging both signals does that one alone does not. Evidence comes from large human trials in adults with type 2 diabetes or obesity. The same molecule is registered in Australia as the prescription medicine Mounjaro; this research material is not that product.
Read the full research note →| Presentation | Code | Status | Price |
|---|---|---|---|
| 15mg | TR15 | In stock | $110 |
3 published reports for Tirzepatide, listed by presentation and batch. Where a batch reference is shown, match it to the batch on the vial label; a report for an earlier batch is historical documentation and does not describe the batch currently supplied. Where no batch reference is published, the report cannot be matched to a vial and is historical documentation only. Each report describes the sample and the tests shown on it. A purity result does not by itself establish identity, quantity, sterility or endotoxin status unless those tests appear on the report, and a report for one batch does not describe another.
| Presentation | Report | Batch | |
|---|---|---|---|
| 15mg | manufacturer certificate | B.4.26 | Open |
| 15mg | independent laboratory report | B.4.26 | Open |
| 15mg | independent laboratory report | B.4.26 | Open |
Supplied as lyophilised (freeze-dried) powder in a sealed vial. Store sealed and protected from light at the conditions stated on the product label or supplied specification. Solvent choice, concentration and handling after reconstitution depend on the compound and on the laboratory’s own procedures, and are not specified here.
Tirzepatide is registered in Australia as the prescription medicine Mounjaro (Eli Lilly Australia, ARTG 379330 and related entries); that registration applies to the manufactured medicine, not to research material. In the United States the FDA has approved it as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management.
Status checked 2026-09-23. Details and sources in the research note.